Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is an alpha-1-adrenergic blocking agent that is used for treatment of arterial hypertension and of obstructive symptoms resulting from benign prostatic hypertrophy.
Oral administration once a day.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic characteristics (moderately elevated molecular weight and high plasma protein binding and large volume of distribution, make it very unlikely its excretion into breast milk in significant amounts and its subsequent absorption by the infant.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Anderson 2018, Malachias 2016, Schaefer 2007 p685), especially during the neonatal period and in case of prematurity